Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

NCT00085696 is registered in ClinicalTrials.gov with Millennium Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00085696
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00085696 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma
Lead sponsor
Millennium Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2004
Completion date
Not reported
Enrollment
66
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, follicular lymphoma, marginal lymphoma